TWD
CRSP icon

True Wealth Design’s CRISPR Therapeutics CRSP Stock Holding History

True Wealth Design’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$679 – 809
2023
Q1 		$679 Buy
+15
New +$729 ﹤0.01% 465

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

True Wealth Design's CRSP Position: Q2 2023 in Review

True Wealth Design sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 15 shares — an estimated $679 sold.

True Wealth Design first reported a position in CRSP in Q1 2023 and held it in 1 quarter. The position peaked at $679 in Q1 2023. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

  • True Wealth Design reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
  • True Wealth Design sold 15 CRISPR Therapeutics shares in Q2 2023, an estimated $679.
  • True Wealth Design first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 1 quarter.
  • True Wealth Design's CRISPR Therapeutics position peaked at $679 in Q1 2023.
  • 418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on True Wealth Design's 13F filing for Q2 2023, filed 14 Aug 2023.